Live tape
Top 8, mentions 7d14,369NVDA4,870 mentions▲ +0.04GOOGL2,064 mentions▲ +0.04SPY1,738 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,112 mentions▲ +0.05TSLA957 mentions▲ +0.04SNDK862 mentions▲ +0.06

Equity · Healthcare

BIO

NYSE

Bio-Rad Laboratories (BIO)

388.79 USD +1.80% vs prior close Nov 9, 2026
Bio-Rad Laboratories, Inc. price graph
63 sessions
400 340 12 Aug 9 Nov

The line runs 362.31 USD on 12 August through 388.79 USD on 9 November, on a scale from 340 to 400. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView
Market cap
10.5B USD
P/E (TTM)
10.3
Revenue, year to Dec 2025
2.6B USD
EPS, diluted, year to Dec 2025
27.85 USD
52-week range
242 USD – 390.31 USD
Avg volume
17.5K

as of Nov 9, 2026

Which funds hold Bio-Rad Laboratories (BIO)?

1 of the 45 institutional funds we track reported a Bio-Rad Laboratories position for the quarter ended 30 Sep 2026 — a combined 43.3M USD; the latest of those filings landed 06 Nov 2026.

Form 13F

Which funds hold Bio-Rad Laboratories (BIO)?
FundPositionSharesValueShares q/q
Fisher Asset ManagementHeld (±25%)114,71943.3M USD−1.9%

Have members of Congress traded Bio-Rad Laboratories (BIO)?

The most recent congressional trade disclosed in Bio-Rad Laboratories is a sale by Lois Frankel (house, FL), dated 08 Sep 2023.

STOCK Act disclosures

Have members of Congress traded Bio-Rad Laboratories (BIO)?
TradedMemberTypeAmountFiled after
08 Sep 2023Lois Frankelhouse · Democrat–FLSale1K USD–15K USD32 days
29 Jun 2023Lois Frankelhouse · Democrat–FLPurchase1K USD–15K USD29 days
28 Jun 2023Lois Frankelhouse · Democrat–FLPurchase1K USD–15K USD30 days
30 Nov 2022Susie Leehouse · Democrat–NVSale1K USD–15K USD29 days
05 Jan 2021Susie Leehouse · Democrat–NVSale1K USD–15K USD36 days
02 Oct 2020Susie Leehouse · Democrat–NVSale1K USD–15K USD67 days
27 May 2020Susie Leehouse · Democrat–NVSale1K USD–15K USD19 days

What has been filed or recorded for Bio-Rad Laboratories (BIO)?

The filings we hold for Bio-Rad Laboratories, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Bio-Rad Laboratories (BIO)?
And
14 Oct 2026Fails to deliverShares failed to deliver336 shares122K USD notional · 0.001% of shares out
09 Oct 2026Fails to deliverShares failed to deliver59 shares21K USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS 17.02 USDRevenue $656M
30 Sep 2026FinancialsTotal assets10.8B USDat period end
30 Sep 2026FinancialsTotal equity7.6B USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS 13.85 USDRevenue $651M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −19.55 USDRevenue $592M
31 Dec 2025Annual reportFY 2025 reportedEPS 27.85 USDRevenue $2.58B
31 Dec 2025FinancialsRevenue2.6B USDfiscal year
31 Dec 2025FinancialsNet income759.9M USDfiscal year
31 Dec 2025FinancialsDiluted EPS27.85 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −12.70 USDRevenue $653M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS 11.67 USDRevenue $652M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS 2.29 USDRevenue $585M
31 Dec 2024Annual reportFY 2025 reportedEPS −25.57 USDRevenue $2.57B

What do people ask about Bio-Rad Laboratories (BIO)?

From live data
What did Bio-Rad Laboratories shares close at?388.79

Bio-Rad Laboratories closed at 388.79 USD on 9 Nov 2026, up 1.80% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Bio-Rad Laboratories’ market cap?10.5B

Bio-Rad Laboratories is worth 10.5B USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Bio-Rad Laboratories’ P/E ratio?10.3

Bio-Rad Laboratories has a price-to-earnings ratio of 10.3, as of 9 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.

What is Bio-Rad Laboratories’ revenue?2.6B

Bio-Rad Laboratories reported revenue of 2.6B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Which funds own Bio-Rad Laboratories?1 of 45

1 of the 45 funds we track reported a Bio-Rad Laboratories position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds

Have members of Congress traded Bio-Rad Laboratories?7 trades

Yes. 7 trades in Bio-Rad Laboratories appear in the congressional disclosures we hold; the latest is a sale by Lois Frankel (House, FL) dated 8 Sep 2023, filed 10 Oct 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

When did Bio-Rad Laboratories last report earnings?17.02

Bio-Rad Laboratories last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 17.02 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGAR13F filings
  4. Wikimedia CommonsPortraits via Wikimedia Commons. Susie Lee: Eric Connolly, Public domain; Lois Frankel: U.S. Government, Public domain.
  5. House disclosuresU.S. House of Representatives financial disclosures
  6. SECSEC fails-to-deliver (CNS) data
  7. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  8. SEC EDGARreported earnings figures and scheduled report dates
  9. SEC EDGARValuation computed from SEC EDGAR filings